Medical Marijuana, Inc. (MJNA): Exclusive Patent Sets Stage for Value Creation
Ryan Allway
July 6th, 2016
News, Top News
The United States’ government has long regarded marijuana as a Schedule I Controlled Substance – alongside LSD and MDMA – that has no accepted medical value. In 1998, Nobel Laureate Julius Axelrod and a group of scientists working for the National Institute of Health filed Patent #6,630,507 titled “Cannabinoids as antioxidants and neuroprotectants”, which seemed to contradict the government’s own claims that cannabis had no medical value whatsoever.
In the coming weeks, the U.S. Drug Enforcement Administration (DEA) will decide whether or not to reclassify marijuana and acknowledge its potential benefits. The U.S. Food and Drug Administration (FDA) has already submitted its recommendation, but DEA Administrator Chuck Rosenberg has not disclosed that recommendation to the public. The decision is expected to have wide-ranging implications on the marijuana market as a whole.
The DEA could de-schedule the drug entirely, which would open the door for medical and recreational marijuana throughout the U.S. Or, the organization could pursue a Schedule II classification that would open the door to strict regulation by the DEA and introduce an approval process for drug indications. These moves would follow the organization’s relaxation of CBD requirements in late-2015 and the approval of a PTSD study earlier this year. Considering that the PTSD trial was originally proposed in 2010, these developments show a definite trend in the relaxation of the DEA’s approach.
In this article we will look at Medical Marijuana Inc. (OTC: MJNA), a company that stands to benefit from the potential reclassification of marijuana in a number of ways. Medical Marijuana was the first public company in the legal cannabis industry and is involved in a wide array of hemp- and cannabis-based business ventures. The one we will focus on today is MJNA’a portfolio company Kannalife™ Sciences which holds two licenses to the NIH’s so-called ‘507’ patent on cannabinoids.
Working with the NIH
KannaLife Sciences holds one exclusive license with the National Institute of Health Office of Technology Transfer (NIH=OTT) for the commercialization of the ‘507’ patent on cannabinoids as antioxidants and neuroprotectants to treat Hepatic Encephalopathy (HE), and a second license to treat Chronic Traumatic Encephalopathy (CTE). As the only set of indications patented by the government’s own scientists, the company is uniquely positioned to both defend its research in the face of any regulatory scrutiny and capitalize on a significant potential market.
The company’s scientific team has a track record of successfully developing drugs from plant-based sources with deep expertise in phyto-pharmacology, biochemistry, and Ayurvedic sciences. Currently, the company is conducting research at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA.
With a 16.7% stake in the company, Medical Marijuana Inc. is a publicly traded entity that gives any investor the chance to capitalize on the unique patent licensing opportunity along with numerous other opportunities across its other subsidiaries.
CTE Awareness on the Rise
CTE awareness has been on the rise over the past several years following the NFL’s $765 million settlement with players over head injuries in August of 2013. In early 2014, the settlement was expanded to exceed $1 billion over 65 years with brain autopsies confirming that an alarmingly high number of players suffered from CTE. The condition has also been documented in other professional sports, including ice hockey, wrestling, and other contact and collision sports.
CTE is a form of encephalopathy that results from the accumulation of tau protein. Unfortunately, early signs are difficult to detect since the symptoms of aggression, memory loss, confusion, and depression manifest years after the trauma. The rapid succession of the disease after the onset leads to suicidal death and postmortem diagnosis is the only method showing the true extent of the disease in the individual.
Dr. Bennet Omalu, MD, was the first person to identify, describe, and name CTE as a disease in football and worked with KannaLife prior to the release of the Hollywood movie Concussion (with Will Smith portraying Dr. Omalu as the main character), that premiered in December 2015. He originally discovered the condition when conducting a full autopsy of decreased NFL Hall of Fame center for the Pittsburg Steelers, Mike Webster, which was featured in the 2013 documentary League of Denial that brought the issue to the public eye.
KannaLife’s new molecule, KLS-13019, is a CBD-like molecule that has shown superior performance in terms of neuroprotection in pre-clinical studies. The company filed a provisional patent application on the molecule and intends to seek an orphan drug designation from the FDA that could fast-track its commercialization and secure seven years of exclusivity.
Looking Ahead
Medical Marijuana Inc.’s investment in KannaLife and other entities focused on clinical trials makes it a unique opportunity ahead of the DEA’s potential rescheduling of marijuana. While many companies are selling the drug to consumers or studying the drug without patents, the company’s clinical focus and ‘507’ patent provide a defensible and potentially lucrative opportunity, especially in the event of a Schedule II re-classification.
Investors can learn more at www.medicalmarijuanainc.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
NanoSphere Health Sciences is a biotechnology company that has developed and is commercializing its patent-pending NanoSphere Delivery SystemTM, a ground breaking platform using nanotechnology for the delivery of biological agents such as cannabinoids, supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond.
Resolve Digital Health Inc. committed to establishing a standard of care missing from the medical cannabis industry until now.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
